---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-038297"
form_type: "8-K"
ticker: "BCTX"
cik: "0001610820"
company_name: "BriaCell Therapeutics Corp."
filed_at: "2023-10-25T23:59:59+00:00"
generated_at: "2026-06-09T10:49:21.116937+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# BriaPro subsidiary files financials; spinout of cancer assets completed Aug 31, 2023

## Summary
- BriaPro filed Jul 31, 2023 financials: $1 cash, zero revenue, inactive during period.
- On Aug 31, 2023, BriaPro closed spinout of Bria-TILsRx and PKCδ inhibitors from parent BriaCell.
- Spinout consideration: 47,945,178 BriaPro shares issued; BriaCell owns ~31,963,452 (2/3).
- BriaCell options/warrants adjusted; 2,131,400 options and 8,121,650 warrants outstanding with split exercise prices.
- BriaPro notes going concern uncertainty; will need additional financing to develop assets.

## SEC filing metadata
- accession: 0001493152-23-038297
- form_type: 8-K
- ticker: BCTX
- cik: 0001610820
- company_name: BriaCell Therapeutics Corp.
- filed_at: 2023-10-25T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1610820/000149315223038297/0001493152-23-038297-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1610820/000149315223038297/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-038297
- JSON: https://secwatch.observer/filing/0001493152-23-038297.json
- Plain text: https://secwatch.observer/filing/0001493152-23-038297.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.